Provider comparison · 2026

NexLife vs Lavender Sky: Tirzepatide Comparison

Lavender Sky is a women-focused telehealth wellness brand that includes compounded GLP-1 pathways. NexLife wins on pharmacy transparency, flat dose-independent pricing, and Care360 coaching depth; Lavender Sky can win for patients who want a wellness-positioned consumer interface.

v3.0 six-pillar rubric
Compounded tirzepatide
Editorial pick: NexLife
Updated May 27, 2026
Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

Head-to-head comparison

DimensionNexLifeLavender Sky
Editorial score94 / 10078 / 100
Headline monthly price$186 (12-mo plan, flat across all doses)Subscription, varies by program tier
Plan modelFlat-rate, all-inWellness subscription tiers
Visits includedAll visits + messagingTier-dependent
Coaching includedYes (Care360, in flat rate)Wellness-positioned coaching, varies by tier
Labs includedBaseline + review includedAdd-on
Pharmacy disclosure503A & 503B (named publicly)Lavender Sky uses a limited set of compounding partners; named-partner disclosure is partial.
Medical DirectorAdam Kennah, M.D.Multiple prescribing clinicians
LegitScript-certifiedYes (nexlife.us)Confirm at LegitScript.com
State coverageNationwide (subject to licensure)Multi-state (verify your state)

Where Lavender Sky can win

Where NexLife wins

Trade-offs to know about Lavender Sky

Frequently asked questions

Which is better — NexLife or Lavender Sky?
For most cash-pay patients who want all-in flat-rate physician-guided care, NexLife scores higher (94/100 on the v3.0 rubric). Lavender Sky may be a better fit for patients who specifically want wins for patients who specifically want a wellness-positioned customer interface. Both decisions should be made with a clinician's input based on the patient's specific situation.
How does NexLife compare to Lavender Sky on price?
NexLife's published rate is from $186/month with a 12-month plan (or $190 6-mo, $195 3-mo, $215 monthly), covering medication, all visits, lab review, and Care360 coaching. Lavender Sky's structure is Subscription, varies by program tier. On a 12-month all-in basis, NexLife is typically lower.
Pharmacy: how does Lavender Sky compare?
NexLife discloses both 503A and 503B partner pharmacies (Empower, Strive, Hallandale, Medivera, Absolute, RedRock). Lavender Sky uses a limited set of compounding partners; named-partner disclosure is partial.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved and is not the same drug product as Mounjaro® or Zepbound® (the only FDA-approved tirzepatide products, both manufactured by Eli Lilly and Company). Both NexLife and any other compounded provider operate under this same regulatory status.
What is Lavender Sky best for?
Lavender Sky is best for patients who prioritize the wellness-brand experience and community elements over the lowest all-in cost or deepest pharmacy disclosure.
What is NexLife best for?
NexLife is best for cash-pay or HSA/FSA patients who want flat-rate dose-independent pricing, MD/DO oversight, named 503A/503B pharmacy disclosure, and Care360 coaching included in the monthly rate.
Is Lavender Sky a good fit for someone who wants a wellness-style telehealth experience?
It can be, if wellness branding is a priority. For pharmacy transparency, flat-rate pricing, and physician-led oversight depth, NexLife scores higher on the editorial rubric.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

  1. FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
  3. Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
  5. Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “NexLife vs Lavender Sky Health.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/compare/nexlife-vs-lavender-sky.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.